Decline in Sales of High-Margin Surgical Products
First written in FY2018-Q1. 13 of 18 entries say "Mitigated", first in FY2018-Q3. Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3MitigatedAnnual report
「Sales and profit increased from the same period of the previous year as sales of ophthalmic knives used in cataract surgery remained strong in Asia, particularly China, Europe, North America and other regions.」
In contrast to the past decline in sales of products making a significant contribution to profit, strong ophthalmic knife sales in Asia, Europe and North America resulted in segment profit of ¥1,992 million for surgical-related products, up 33.7% year on year. - FY2024-Q2MitigatedAnnual report
「Sales and profit increased year on year as demand for ophthalmic knives used in cataract surgery expanded in Asia, led by China, and in Europe and other regions.」
In contrast to the past situation in which declining sales of products making a significant contribution to profit were an issue, surgical-related products recorded higher sales and profit as demand for ophthalmic knives expanded in Asia, Europe and other regions. - FY2024-Q1MitigatedAnnual report
「Sales and profit increased from the same period of the previous year as demand for highly regarded ophthalmic knives expanded in Asia, particularly China, as well as Japan, Europe, North America and other regions.」
In contrast to the past decline in sales of products making a significant contribution to profit, expanding demand for ophthalmic knives in Asia, Japan, Europe and North America resulted in an 18.8% increase in sales and a 36.7% increase in segment profit for surgical-related products. - FY2023MitigatedAnnual report
「Sales increased year on year as demand for ophthalmic knives used in cataract surgery expanded in Asia, Europe and other regions. Segment profit also increased, despite higher manufacturing-related costs, due in part to the increase in sales.」
In contrast to the past situation in which declining sales of products making a significant contribution to profit were an issue, surgical-related products recorded higher sales and profit as demand for ophthalmic knives expanded in Asia and Europe. - FY2023-Q1MitigatedAnnual report
「Sales and profit increased year on year as demand for highly regarded ophthalmic knives expanded in Asia, led by China, and in Japan.」
In contrast to the previously reported decline in sales of products making a significant contribution to profit, surgical-related products recorded higher sales and profit as demand for ophthalmic knives expanded in Asia, led by China, and in Japan. - FY2022-Q3MitigatedAnnual report
「Sales were ¥4,388 million, up 20.8% year on year, as sales of highly regarded ophthalmic knives remained strong in Europe, Asia and Japan. The increase in sales and other factors resulted in segment profit (operating profit) of ¥1,531 million, up 24.0%.」
Strong ophthalmic knife sales in Europe, Asia and Japan resulted in a 20.8% increase in sales and a 24.0% increase in segment profit for surgical-related products. - FY2022-Q2MitigatedAnnual report
「Sales were ¥2,780 million, up 22.4% year on year, as sales of highly regarded ophthalmic knives remained strong in China and Japan. The increase in sales and other factors resulted in segment profit (operating profit) of ¥973 million, up 30.6%.」
For surgical-related products, strong ophthalmic knife sales in China and Japan resulted in a 22.4% increase in sales and a 30.6% increase in segment profit. - FY2021MitigatedAnnual report
「The increase in sales and other factors resulted in segment profit (operating profit) of ¥1,557 million, up 21.7%.」
Although the impact of sluggish domestic and European sales under COVID-19 remained, higher sales in China and Europe resulted in a 21.7% year-on-year increase in segment profit for surgical-related products. - FY2021-Q3MitigatedAnnual report
「Higher sales of products making a significant contribution to profit and other factors resulted in segment profit (operating profit) of ¥1,235 million, up 15.4%.」
Against the previously reported risk of declining sales of high-margin products and products making a significant contribution to profit, the Company reported higher sales of products making a significant contribution to profit and a 15.4% increase in segment profit for surgical-related products. - FY2021-Q2RestatedAnnual report
「Sales were ¥2,272 million, down 4.8% year on year. Sales of highly regarded ophthalmic knives increased in China, but sales, particularly in Japan, remained sluggish because surgeries were restricted amid the spread of COVID-19.」
Ophthalmic knife sales increased in China, while surgery restrictions related to COVID-19 continued to weigh on domestic sales and resulted in lower sales of surgical-related products. - FY2021-Q1MaterialisedAnnual report
「Sales were ¥1,152 million, down 7.6% year on year. Sales of highly regarded ophthalmic knives remained strong in China, but sales, particularly in Japan and Europe, were sluggish because surgeries were restricted amid the spread of COVID-19.」
Ophthalmic knife sales were strong in China, while surgery restrictions related to COVID-19 weakened sales in Japan and Europe, resulting in a 7.6% decline in sales of surgical-related products. - FY2020MaterialisedAnnual report
「Sales were ¥4,916 million, down 9.7% year on year, as sales, particularly in Europe, remained sluggish because nonessential and nonurgent surgeries were restricted amid the global spread of COVID-19. Segment profit (operating profit) was ¥1,341 million, down 25.6%, due in part to the decline in sales.」
Surgery restrictions related to COVID-19 weakened sales in Europe, and the full-year impact of declining sales of products making a significant contribution to profit emerged as lower sales and segment profit for surgical-related products. - FY2020-Q3MaterialisedAnnual report
「Sales were ¥3,823 million, down 6.6% year on year. Sales of highly regarded ophthalmic knives remained strong in Japan, but sales, particularly overseas, were sluggish because nonessential and nonurgent surgeries were restricted amid the global spread of COVID-19. Segment profit (operating profit) was ¥1,120 million, down 15.6%, due in part to a decline in sales of products making a significant contribution to profit.」
The previously subdued decline in sales of high-margin products and products making a significant contribution to profit recurred amid surgery restrictions related to COVID-19 and was cited as a factor behind the decline in profit from surgical-related products. - FY2019-Q3MitigatedAnnual report
「Higher sales of high-margin products and other factors resulted in segment profit (operating profit) of ¥1,327 million, up 29.6%.」
For surgical-related products, the Company reported higher sales of high-margin products and a 29.6% increase in segment profit. - FY2019-Q2MitigatedAnnual report
「In addition to the increase in sales, higher sales of high-margin products and other factors resulted in segment profit (operating profit) of ¥876 million, up 33.0%.」
For surgical-related products, the previously reported decline in sales of high-margin products reversed, with higher sales of high-margin products and a 33.0% increase in segment profit reported. - FY2018MitigatedAnnual report
「Sales were ¥4,729 million, up 11.6% year on year, as sales of highly regarded ophthalmic knives remained strong in Japan and overseas, and sales of staplers increased. Segment profit (operating profit) was ¥1,354 million, up 10.9%, due in part to the increase in sales.」
The previously cited pressure from declining sales of high-margin products was not repeated, while surgical-related products recorded higher sales and profit due to increased sales of ophthalmic knives and other products. - FY2018-Q3MitigatedAnnual report
「Sales were ¥3,595 million, up 15.5% year on year, as sales of highly regarded ophthalmic knives remained strong in Japan, China and Russia. Segment profit (operating profit) was ¥1,024 million, up 14.1%, due in part to the increase in sales.」
The previously cited decline in sales of high-margin products was not mentioned again, while strong ophthalmic knife sales and higher sales and profit for surgical-related products were reported. - FY2018-Q1First statedAnnual report
「Sales were ¥1,173 million, up 12.9% year on year, as sales of highly regarded ophthalmic knives remained strong in Japan and overseas. Despite the increase in sales, segment profit (operating profit) was ¥338 million, up 4.4%, due in part to a decline in sales of high-margin products and an increase in selling, general and administrative expenses.」
Surgical-related products recorded higher sales and profit, while the decline in sales of high-margin products was mentioned for the first time as a factor explaining segment profit.